SYNTAX analysis finds treatment with TAXUS(R) Express(2)(R) Stent System more cost effective than bypass surgery in patients with complex coronary artery disease system

    VANCOUVER, May 20 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP) today announced that its corporate partner, Boston Scientific
Corporation (NYSE:   BSX) has reported results from an analysis of economic and
quality of life outcomes, based on one-year data from its landmark SYNTAX
trial. The results found that percutaneous coronary intervention (PCI) using
the TAXUS(R) Express(2)(R) Paclitaxel-Eluting Coronary Stent System was
consistently associated with fewer patient hospital days during the first year
after treatment compared to coronary artery bypass graft (CABG) surgery. Total
medical costs at one year were also lower with PCI. Analysis of the data was
presented by Ben van Hout, Ph.D., of the University of Utrecht, The
Netherlands, at the annual EuroPCR Scientific Program in Barcelona.
    "This analysis demonstrates that although hospitalization patterns vary
by country, PCI patients consistently benefit from shorter hospital stays
during the first year following treatment, as compared to CABG patients," said
Dr. van Hout. "This analysis will be especially helpful to physicians and
hospital administrators as they consider the most cost-effective course of
treatment for these complex patients."
    "Today's findings reinforce previously announced results on economic and
quality of life data from the SYNTAX trial," said Keith D. Dawkins, M.D.,
Associate Chief Medical Officer of Boston Scientific. "The data show that PCI
benefits patients and the health care system overall with shorter hospital
stays, increased quality adjusted life years and lower total costs. When
coupled with safety and efficacy data from the larger SYNTAX data set, this
analysis supports PCI as a cost-effective treatment option for these
challenging patients."
    The SYNTAX economic analysis compared quality of life outcomes using
standardized health outcome measures(1) and resource utilization associated
with PCI and CABG surgery in patients in 11 European countries and the U.S.
who qualified for one or the other revascularization option. The results
indicated a short-term benefit for PCI versus CABG surgery, with no
significant difference at one year, but with a gain in quality adjusted life
years (QALY) of 0.02 in favor of PCI.
    The analysis also included a detailed calculation of total medical costs
at one year for all patients treated in the U.K., the country with the largest
cohort of patients. Total costs included the initial procedure, all
hospitalizations, repeat procedures and medication. Although initial procedure
costs were similar ((pnds stlg)4,201 for PCI vs. (pnds stlg)4,246 for CABG),
total medical costs for PCI were 25 percent lower than CABG at one year ((pnds
stlg)8,295 PCI vs. (pnds stlg)11,101 CABG, p(less than)0.001). The lower
medical costs coupled with the net improvement in quality of life resulted in
PCI as the dominant treatment strategy at one year.
    Results further showed that although the average length of hospital stay
varied by country, CABG patients were hospitalized on average an additional
7.8 days compared to PCI patients (13.7 vs. 5.9 days, including pre- and
    SYNTAX is the first randomized, controlled clinical trial to compare PCI
using the TAXUS(R) Express(2)(R) Paclitaxel-Eluting Coronary Stent System to
CABG surgery in patients with left main disease and/or significant narrowing
of all three coronary arteries (three-vessel disease). These complex patients
are traditionally treated with CABG surgery and have been excluded from most
prior drug-eluting stent clinical trials. The SYNTAX trial provides important
data related to the treatment of these complex patients and should help
physicians make more informed treatment decisions.
    It has been previously reported that one-year SYNTAX data demonstrated
comparable safety for the two treatment groups, with no overall statistically
significant differences between PCI and CABG surgery in rates of death or
myocardial infarction (MI, or heart attack), although there were more strokes
in patients treated with CABG surgery. The rate of repeat revascularization
was higher in the PCI group, although most procedures in the PCI group were
repeat PCI, with only a small percentage requiring CABG surgery. However,
because of the increased need for repeat procedures, the overall 12-month
MACCE (Major Adverse Cardiovascular or Cerebrovascular Event rate, including
all-cause death, stroke, MI and repeat revascularization) was higher for PCI.
    The safety and effectiveness of the TAXUS Express(2) Stent System have
not been established in patients with left main or three-vessel disease.

    (1) The measure used was the EuroQoL EQ-5D, which assesses patient
        mobility, self care, usual activities, pain/discomfort and

    Forward Looking Statements
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research, development, product
and drug development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for
substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission ("SEC") and
applicable Canadian regulatory authorities. For a more thorough discussion of
the risks associated with our business, see the "Risk Factors" section in our
annual report for the year ended December 31, 2008 filed with the SEC on Form
10-K, and our quarterly report for the three months ended March 31, 2009 filed
with the SEC on Form 10-Q.

    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at

For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890